pdufa.bio

LYTENAVA (bevacizumab-vikg)

Updated ยทnext FDA decision on the calendar

LYTENAVA (bevacizumab-vikg) The FDA approved it on Jul 24, 2026. 4 FDA decisions on record below. Every date links its source.

OTLK catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

We track 4 catalyst events for this program: 0 upcoming and 4 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

PDUFA · Dec 31, 2025 CRLOTLKPDUFA · Mar 5, 2026 CRLOTLKPDUFA · Apr 7, 2026 CRLOTLKPDUFA · Jul 24, 2026 ✓ ApprovedOTLK

Questions

When is LYTENAVA (bevacizumab-vikg)'s next FDA decision or readout?

No upcoming catalyst is on our calendar for LYTENAVA (bevacizumab-vikg); 4 FDA decisions are on record below.

What happened at LYTENAVA (bevacizumab-vikg)'s most recent FDA decision?

On Jul 24, 2026 the FDA approved the application. The decision page carries the source document and the measured share-price reaction.

Has LYTENAVA (bevacizumab-vikg) been approved by the FDA?

Yes. The FDA approved an application for LYTENAVA (bevacizumab-vikg) on Jul 24, 2026; the decision page linked above carries the source.

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings; every date on this page links its source.